Spinal cord injury (SCI) induces the upregulation of chondroitin sulfate proteoglycans (CSPGs) at the glial scar and inhibits neuroregeneration. Under normal physiological condition, CSPGs interact with hyaluronan (HA) and other extracellular matrix on the neuronal surface forming a macromolecular structure called perineuronal nets (PNNs) which regulate neuroplasticity. 4-methylumbelliferone (4-MU) is a known inhibitor for HA synthesis but has not been tested in SCI. We first tested the effect of 4-MU in HA reduction in uninjured rats. After 8 weeks of 4-MU administration at a dose of 1.2 g/kg/day, we have not only observed a reduction of HA in the uninjured spinal cords but also a down-regulation of CS glycosaminoglycans (CS-GAGs). In order to assess the effect of 4-MU in chronic SCI, six weeks after Th8 spinal contusion injury, rats were fed with 4-MU or placebo for 8 weeks in combination with daily treadmill rehabilitation for 16 weeks to promote neuroplasticity. 4-MU treatment reduced the HA synthesis by astrocytes around the lesion site and increased sprouting of 5-hydroxytryptamine fibres into ventral horns. However, the current dose was not sufficient to suppress CS-GAG up-regulation induced by SCI. Further adjustment on the dosage will be required to benefit functional recovery after SCI.

Department of Neuroscience Charles University 2nd Faculty of Medicine 15006 Prague Czech Republic

Faculty of Biological Sciences University of Leeds Leeds LS2 9JT UK

Institute of Experimental Medicine Czech Academy of Sciences Vídeňská 1083 Prague Czech Republic

Institute of Physics Czech Academy of Sciences 182 21 Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc24000723

003      

CZ-PrNML

005      

20240213093335.0

007      

ta

008      

240109s2023 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1038/s41598-023-46539-5 $2 doi

035    __

$a (PubMed)37932336

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Štepánková, Kateřina $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic. katerina.stepankova@iem.cas.cz $u Department of Neuroscience, Charles University, Second Faculty of Medicine, 15006, Prague, Czech Republic. katerina.stepankova@iem.cas.cz

245    10

$a Low oral dose of 4-methylumbelliferone reduces glial scar but is insufficient to induce functional recovery after spinal cord injury / $c K. Štepánková, M. Chudíčková, Z. Šimková, N. Martinez-Varea, Š. Kubinová, LM. Urdzíková, P. Jendelová, JCF. Kwok

520    9_

$a Spinal cord injury (SCI) induces the upregulation of chondroitin sulfate proteoglycans (CSPGs) at the glial scar and inhibits neuroregeneration. Under normal physiological condition, CSPGs interact with hyaluronan (HA) and other extracellular matrix on the neuronal surface forming a macromolecular structure called perineuronal nets (PNNs) which regulate neuroplasticity. 4-methylumbelliferone (4-MU) is a known inhibitor for HA synthesis but has not been tested in SCI. We first tested the effect of 4-MU in HA reduction in uninjured rats. After 8 weeks of 4-MU administration at a dose of 1.2 g/kg/day, we have not only observed a reduction of HA in the uninjured spinal cords but also a down-regulation of CS glycosaminoglycans (CS-GAGs). In order to assess the effect of 4-MU in chronic SCI, six weeks after Th8 spinal contusion injury, rats were fed with 4-MU or placebo for 8 weeks in combination with daily treadmill rehabilitation for 16 weeks to promote neuroplasticity. 4-MU treatment reduced the HA synthesis by astrocytes around the lesion site and increased sprouting of 5-hydroxytryptamine fibres into ventral horns. However, the current dose was not sufficient to suppress CS-GAG up-regulation induced by SCI. Further adjustment on the dosage will be required to benefit functional recovery after SCI.

650    _2

$a zvířata $7 D000818

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a chondroitinsulfát proteoglykany $7 D011508

650    12

$a glióza $x patologie $7 D005911

650    _2

$a kyselina hyaluronová $7 D006820

650    _2

$a hymekromon $x terapeutické užití $7 D006923

650    _2

$a mícha $x patologie $7 D013116

650    12

$a poranění míchy $7 D013119

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Chudíčková, Milada $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic

700    1_

$a Šimková, Zuzana $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic

700    1_

$a Martinez-Varea, Noelia $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic $u Department of Neuroscience, Charles University, Second Faculty of Medicine, 15006, Prague, Czech Republic

700    1_

$a Kubinová, Šárka $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic $u Institute of Physics, Czech Academy of Sciences, 182 21, Prague, Czech Republic

700    1_

$a Urdzíková, Lucia Machová $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic. lucia.machova@iem.cas.cz $u Department of Neuroscience, Charles University, Second Faculty of Medicine, 15006, Prague, Czech Republic. lucia.machova@iem.cas.cz

700    1_

$a Jendelová, Pavla $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic. pavla.jendelova@iem.cas.cz $u Department of Neuroscience, Charles University, Second Faculty of Medicine, 15006, Prague, Czech Republic. pavla.jendelova@iem.cas.cz

700    1_

$a Kwok, Jessica C F $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská, 1083, Prague, Czech Republic. j.kwok@leeds.ac.uk $u Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK. j.kwok@leeds.ac.uk

773    0_

$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 19183

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37932336 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240109 $b ABA008

991    __

$a 20240213093332 $b ABA008

999    __

$a ok $b bmc $g 2049384 $s 1210417

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 13 $c 1 $d 19183 $e 20231106 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195

GRA    __

$p Wellcome Trust $2 United Kingdom

GRA    __

$a WT104818MA $p Wellcome Trust $2 United Kingdom

GRA    __

$a MC-PC-16050 $p Medical Research Council $2 United Kingdom

LZP    __

$a Pubmed-20240109